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The authors of this paper have advised us that by mistake they uploaded the wrong figure files for [Figures 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"} which had not been correctly updated.

In [Figure 2](#F0002){ref-type="fig"}, the percentages within the figure do not match with what is reported in the text. As a result, they have provided the correct artwork below which should replace the existing image for [Figure 2](#F0002){ref-type="fig"} in their paper. Figure 2Bimekizumab efficacy in treating plaque psoriasis patients, assessed in a phase II trial. Clinical outcomes in psoriasis patients after 12-week therapy with placebo or different bimekizumab dosages.**Abbreviations:** BKZ, bimekizumab; BSA, body surface area; IGA, investigator global assessment; N, number; PASI, psoriasis area severity index; pts, patients; Q4, every 4 weeks; R, randomization; tot., total; w, weeks.

In [Figure 3](#F0003){ref-type="fig"}, to be consistent with [Figure 2](#F0002){ref-type="fig"}, the author has changed just one label of one treatment group. As a result, they have provided the correct artwork below which should replace the existing image for [Figure 3](#F0002){ref-type="fig"} in their paper. Figure 3Bimekizumab efficacy in treating psoriatic arthritis patients, assessed in a phase II trial. Clinical outcomes in psoriatic arthritis patients after 12-week therapy with placebo or different bimekizumab dosages.**Abbreviations:** ACR, American College of Rheumatology; BKZ, bimekizumab; CASPAR, Classification Criteria for Psoriatic Arthritis; N, number; pts, patients; Q4, every 4 weeks; R, randomization; SJC, swollen joint count; TJC, tender joint count; tot., total; w, weeks.
